Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.38 +0.05 (+0.38%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
Exposures Product Safety
New New Deal Worries
Nio is up 1.4% today on another round of Meme buying. 
Via Talk Markets
Good Times For Gold
Gold is rising some more, in part as an alternative to crypto. 
Via Talk Markets
Sterling At Five-Year High
Today markets are mixed because of currency factors, with sterling bullishness against the dollar and the euro. 
Via Talk Markets
Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection
Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot’s efficacy waned over time but... 
Via Benzinga
Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results
From Takeda Pharmaceutical Company Limited
Via Business Wire
Worldwide Upbeat
The US crackdown on cryptocurrencies continues with the Fed today indicating that an official crypto-currency is going to be created for the USA. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review
The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The... 
Via Benzinga
Exposures Product Safety
Moderna's COVID-19 Vaccine Scores Emergency Use Nod In Japan
Moderna Inc (NASDAQ: MRNA) has received emergency use approval for its mRNA COVID-19 vaccine in Japan. Takeda Pharmaceutical Co Ltd (NYSE: TAK),... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 20) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Is BioCryst a Good Stock to Buy Now?
This commercial-stage drugmaker trades for less than many of its clinical-stage peers. 
Via The Motley Fool
Exposures Product Safety
U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan
From Takeda Pharmaceutical Company Limited
Via Business Wire
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first... 
Via Benzinga
Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit
Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and... 
Via Benzinga
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the... 
Via Benzinga
Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021
From Takeda Pharmaceutical Company Limited
Via Business Wire
Cathie Wood Cuts Apple Stake By 30% And Buys Coinbase, DraftKings
Cathie Wood-led Ark Investment Management shed more shares of Apple Inc (NASDAQ: 
Via Benzinga
Gold Up Four Days In A Row
The dollar is at a nearly 3 month low. 
Via Talk Markets
Cathie Wood Loads Up Another $28M Worth Of Shares In Alibaba Rival JD.Com
Cathie Wood-led Ark Investment Management on Friday bought 366,879 shares, worth about $27.7 million, in JD.com Inc (NASDAQ: JD), a key rival to Alibaba Group Holding (NYSE: BABA... 
Via Benzinga
Cathie Wood Loads Up More On Peloton, Skillz, Teladoc On The Dip
Cathie Wood-led Ark Investment Management snapped up over 3 million shares, worth about $48.53 million, in Skillz Inc (NYSE: SKLZ) on Wednesday. SKLZ shares closed 9% lower... 
Via Benzinga
Cathie Wood Slashes Apple Stake To Half — Also Trims Google, Fastly: What You Need To Know
Cathie Wood-led Ark Investment Management nearly halved the Apple Inc (NASDAQ: AAPL) stake in the ARK Fintech Innovation ETF (NYSE: ARKF) on Thursday. ARKF shed 298,505 Apple... 
Via Benzinga
Monday Markets Unhinged
Today's stock market is somewhat unhinged because so many foreign markets are shut for a bank holiday: Britain, China, Thailand, Japan. 
Via Talk Markets
Another Heavy News Day
For whatever it is worth, markets seem keen on the proposed measures, boosted by a nicely lower level of new unemployment insurance claims last week. 
Via Talk Markets
Arrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has announced positive interim 48-week liver biopsy results from the Phase 2 AROAAT2002 study ... 
Via Benzinga
Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
From Takeda Pharmaceutical Company Limited
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.